ANRO — Alto Neuroscience, Inc. Dilution Risk Tracker

Alto Neuroscience, Inc. (ANRO) has a DilutionScore of 30/100, rated Medium dilution risk. This tier indicates some dilution exposure — often an older shelf registration with remaining capacity, warrants not yet exercised, or a cash position that will require monitoring over the next several quarters. Score as of July 14, 2026.

The most significant dilution vector for ANRO is its shelf registration capacity of $120.0M. A shelf registration (typically an S-3 filing) gives a company pre-approved access to raise capital quickly without a traditional roadshow. The registered amount represents the maximum that can be raised — not necessarily what will be raised — but active shelves combined with tight cash positions are the pattern DilutionWatch monitors most closely.

DilutionWatch tracks over 25 SEC filing types for ANRO in real-time, scanning EDGAR every 60 seconds. A recent S-3 or registration statement filing appears in ANRO's filing history — this warrants monitoring for subsequent prospectus supplements (Form 424B), which indicate active capital raising. Recent 8-K filings are present; material events disclosures can sometimes precede or accompany capital raises. The DilutionWatch screener shows real-time score changes for ANRO alongside comparable medium-risk stocks. Not financial advice — this analysis is for informational purposes only.